Hormone replacement therapy in women with postovariectomy syndrome and endometrial ablation

This study assessed the efficacy and tolerance of combined estrogen–progestagen hormone replacement therapy (Femoston 1/5: 1 mg estradiol + 5 mg dydrogesterone) in 37 women aged 47–52 with moderate to severe postovariectomy syndrome after bilateral adnexectomy and endometrial ablation performed for recurrent endometrial hyperplasia unresponsive to conservative therapy. Across 1.5–2.5 years of follow-up, the therapy markedly reduced clinical symptoms of postovariectomy syndrome, including improvement in hot flush frequency; the paper reports no observed adverse influence on endometrial status based on transvaginal ultrasound monitoring. A key caveat explicitly evident from the design is the small, selected cohort with exclusion of women with endometrial atypia/cancer and several thromboembolic or hormone-dependent malignancy conditions, limiting generalizability. Relevance to endometriosis: endometriosis/adenomyosis are not discussed in this paper; it was included in the corpus via a keyword match related to gynecologic hormone/uterine endometrial procedures.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works